Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From France

Listen to Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest clinical data on immune checkpoint inhibitors for advanced urothelial cancer.
Marine Gross-Goupil, MD, PhD
Alain Ravaud, MD, PhD
Released: November 19, 2020

This episode is in French

In this episode, Alain Ravaud, MD, PhD, and Marine Gross-Goupil MD PhD, discuss in French the latest immuno-oncology developments in the treatment of urothelial cancer.

Presenters:

Alain Ravaud MD PhD
Professor of Medical Oncology
Head of Department of Medical Oncology
Bordeaux University Hospital
Bordeaux, France

Marine Gross-Goupil, MD, PhD
Medical Oncologist
Saint-André Hospital
Bordeaux University Hospital
Bordeaux, France

Acknowledgements

Supported by an educational grant from
Pfizer, Inc. and EMD Serono

Related Content

First results from PEACE-1 trial of abiraterone with or without local radiotherapy plus SOC in metastatic CSPC, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 17, 2021

Downloadable slideset from Eric Jonasch, MD on managing irAEs in patients with advanced RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 16, 2021

Downloadable slideset from Dr Elizabeth R. Plimack on first-line treatment options for patients with RCC, from Clinical Care Options (CCO)

Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Downloadable slideset from Neeraj Agarwal, MD on treatment options for salvage therapy in advanced RCC, from Clinical Care Options (CCO)

Neeraj Agarwal, MD Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue